Lipella pharmaceuticals doses first patient in human study of innovative contrast agent

Lipella awarded $1.35m grant in 2022 for development of intravesical contrast-enhanced magnetic resonance imaging (ice-mri) technology. pittsburgh , april 5, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: lipo) ("lipella" or the "company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces it has dosed the first patient in its human clinical study of a novel bladder mri contrast agent.
LIPO Ratings Summary
LIPO Quant Ranking